News | July 03, 2025
WuXi XDC announces mechanical completion of Singapore site
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The inspection concluded with zero Form 483 observations
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Subscribe To Our Newsletter & Stay Updated
